Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: a prospective evaluation

被引：8
|
作者：
Prati, Veronica [1 ,2 ]
Ruatta, Fiorella [1 ]
Aversa, Caterina [1 ]
Gernone, Angela [3 ]
Galizia, Danilo [4 ]
Bonzano, Alessandro [5 ]
Torino, Sofia [1 ]
Nuzzolese, Imperia [1 ]
Marandino, Laura [1 ]
Aglietta, Massimo [1 ]
Ortega, Cinzia [1 ,2 ]
机构：
[1] IRCCS Candiolo, Fdn Piemonte Oncol, Med Oncol 1, Turin, Italy
[2] ASL CN 2, Med Oncol, Alba E Bra, Cuneo, Italy
[3] Policlin Bari, Med Oncol, Bari, Italy
[4] IRCCS Candiolo, Fdn Piemonte Oncol, Med Oncol 2, Turin, Italy
[5] IRCCS Candiolo, Fdn Piemonte Oncol, Cardiol Unit, Turin, Italy
来源：
FUTURE ONCOLOGY | 2018年 / 14卷 / 05期
关键词：
abiraterone acetate; cardiovascular risk factors; frail patients; metastatic castration resistant prostate cancer; multidisciplinary management; prospective study; safety; SURVIVAL ANALYSIS; DOUBLE-BLIND; GUIDELINES; MEN; CONSEQUENCES; DISEASE; RISK;
D O I：
10.2217/fon-2017-0385
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: The aim of this study is to evaluate cardiotoxicity of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer patients (pts) with cardiovascular comorbidities or coronary artery disease (CAD) risk factors. Patients & methods: We prospectively analyzed pts receiving AA in order to evaluate correlations between cardiotoxicity onset and CAD risk factors or cardiovascular comorbidities. Results: Eightyseven pts were enrolled, with median treatment duration of 9 months (1-44). At baseline, 84 pts (96%) had CAD risk factors. During treatment four pts (4; 6%) developed hypertension and 26 pts (30%) worsened the preexisting hypertension. Median left ventricular ejection fraction were 64 and 63% at baseline and after treatment, respectively. Conclusion: AA appears to be safe in pts with cardiovascular comorbidities or CAD risk factors.
引用
收藏
页码：443 / 448
页数：6
相关论文
共 50 条
  • [1] ABIRATERONE ACETATE: PROSPECTIVE EVALUATION OF THE CARDIOVASCULAR SAFETY PROFILE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS
    Ruatta, Fiorella
    Prati, Veronica
    Aversa, Caterina
    Gernone, Angela
    Galizia, Danilo
    Bonzano, Alessandro
    Torino, Sofia
    Nuzzolese, Imperia
    Marandino, Laura
    Aglietta, Massimo
    Ortega, Cinzia
    [J]. ANTICANCER RESEARCH, 2016, 36 (05) : 2615 - 2615
  • [2] Abiraterone Acetate In Metastatic Castration-Resistant Prostate Cancer
    Yang, Lily P. H.
    [J]. DRUGS, 2011, 71 (15) : 2067 - 2077
  • [3] Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
    Chi, Kim N.
    Rathkopf, Dana
    Smith, Matthew R.
    Efstathiou, Eleni
    Attard, Gerhardt
    Olmos, David
    Lee, Ji Youl
    Small, Eric J.
    Gomes, Andrea J. Pereira De Santana
    Roubaud, Guilhem
    Saad, Marniza
    Zurawski, Bogdan
    Sakalo, Valerii
    Mason, Gary E.
    Francis, Peter
    Ms, George Wang
    Wu, Daphne
    Diorio, Brooke
    Lopez-Gitlitz, Angela
    Sandhu, Shahneen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (18) : 3339 - +
  • [4] Erratum to Abiraterone acetate: in metastatic castration-resistant prostate cancer
    L. P. H. Yang
    [J]. Drugs, 2012, 72 (2) : 192 - 192
  • [5] Abiraterone Acetate (Zytiga) for Metastatic Castration-Resistant Prostate Cancer
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2011, 53 (1370): : 63 - 64
  • [6] Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors
    Procopio, Giuseppe
    Grassi, Paolo
    Testa, Isabella
    Verzoni, Elena
    Torri, Valter
    Salvioni, Roberto
    Valdagni, Riccardo
    de Braud, Filippo
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (05): : 479 - 482
  • [7] Evaluation of factors predicting response to abiraterone acetate in metastatic castration-resistant prostate cancer: A prospective study
    Kumawat, Ghanshyam
    Yadav, S. S.
    Jaiswal, Sanjeev
    Sahu, Ramdayal
    Garg, Anurag
    Tomar, Vinay
    [J]. JOURNAL OF CLINICAL UROLOGY, 2024, 17 (04) : 386 - 394
  • [8] Abiraterone acetate in castration-resistant prostate cancer
    Iacovelli, Roberto
    Palazzo, Antonella
    Procopio, Giuseppe
    Gazzaniga, Paola
    Cortesi, Enrico
    [J]. ANTI-CANCER DRUGS, 2012, 23 (03) : 247 - 254
  • [9] Use of Prednisone With Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
    Auchus, Richard J.
    Yu, Margaret K.
    Nguyen, Suzanne
    Mundle, Suneel D.
    [J]. ONCOLOGIST, 2014, 19 (12): : 1231 - 1240
  • [10] A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration-resistant prostate cancer
    Clayton, Ravinder
    Wu, Jackson
    Heng, Daniel Y.
    North, Scott A.
    Emmenegger, Urban
    Hotte, Sebastien
    Chi, Kim
    Zielinski, Rob
    Al-Shamsi, Humaid
    Chen, Leo
    Eigl, Bernhard
    [J]. CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2014, 8 (9-10): : E583 - E590
12345